In CLL, similar to R/R B‐cell malignancies, cancer cells can evade or resist therapy by losing the CD19 epitope or by suppressing CD19 expression due to genetic alterations such as splice variation, mutations, or lineage switching.21, 22, 23. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.